Market Cap | 6.05M | P/E | - | EPS this Y | 98.50% | Ern Qtrly Grth | - |
Income | -49.84M | Forward P/E | -0.47 | EPS next Y | 65.70% | 50D Avg Chg | 133.00% |
Sales | 11M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -72.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
Recommedations | 3.00 | Quick Ratio | 0.46 | Shares Outstanding | 4.93M | 52W Low Chg | 350.00% |
Insider Own | 7.55% | ROA | -67.64% | Shares Float | 3.35M | Beta | 0.13 |
Inst Own | 21.55% | ROE | - | Shares Shorted/Prior | 316.38K/322.97K | Price | 0.24 |
Gross Margin | -283.22% | Profit Margin | - | Avg. Volume | 63,756,935 | Target Price | 12.00 |
Oper. Margin | -753.80% | Earnings Date | May 21 | Volume | 286,459,715 | Change | 54.29% |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Giffin Brett A. | Chief Commercial Off.. Chief Commercial Officer | Feb 20 | Sell | 0.65 | 537 | 349 | 3,049 | 11/28/23 |
CR Group L.P. | 10% Owner 10% Owner | Sep 27 | Sell | 0.17 | 13,130,147 | 2,232,125 | 09/29/23 | |
CR Group L.P. | 10% Owner 10% Owner | Sep 25 | Sell | 0.25 | 250,000 | 62,500 | 5,021,014 | 09/27/23 |
CR Group L.P. | 10% Owner 10% Owner | Sep 22 | Sell | 0.26 | 5,079,344 | 1,320,629 | 5,088,781 | 09/26/23 |
CR Group L.P. | 10% Owner 10% Owner | Sep 21 | Sell | 0.3 | 6,338,211 | 1,901,463 | 6,465,629 | 09/25/23 |
CR Group L.P. | 10% Owner 10% Owner | Sep 20 | Sell | 0.31 | 7,753,710 | 2,403,650 | 8,183,716 | 09/22/23 |
Gibbs Michael Terrence | General Counsel General Counsel | Mar 28 | Sell | 0.481 | 239 | 115 | 6,612 | 04/06/23 |
Sperzel John J III | Chairman, CEO, and P.. Chairman, CEO, and President | Apr 07 | Buy | 0.50 | 30,000 | 15,000 | 221,773 | 04/11/22 |
Barclay Alec | Chief Operations Off.. Chief Operations Officer | Apr 08 | Buy | 0.50 | 12,952 | 6,476 | 181,945 | 04/11/22 |
Gibbs Michael Terrence | General Counsel General Counsel | Apr 07 | Buy | 0.49 | 10,000 | 4,900 | 166,651 | 04/11/22 |
Sprague John M | Chief Financial Offi.. Chief Financial Officer | Apr 08 | Buy | 0.4767 | 10,000 | 4,767 | 152,350 | 04/11/22 |
Giffin Brett A. | Chief Commercial Off.. Chief Commercial Officer | Apr 08 | Buy | 0.489 | 10,600 | 5,183 | 10,600 | 04/11/22 |